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Abstract: Background: The aberrant expression of microRNAs (miRNAs) has been associated
with several diseases, including cancer, inflammatory, and autoimmune conditions. Interest in
salivary miRNAs as non-invasive tools for the diagnosis of malignancies and systemic diseases
is rapidly increasing. The present systematic review was developed for answering the question:
“Are salivary microRNAs reliable biomarkers for diagnosis of cancer and systemic diseases?” Methods:
The application of inclusion and exclusion criteria led to the selection of 11 papers. Critical appraisals
and quality assessments of the selected studies were performed through the National Institute of
Health “Study Quality Assessment Tool” and the classification of the Oxford Center for Evidence-Based
Medicine. Results: Seven studies reported statistically significant correlations between one or more
salivary miRNAs and the investigated disease. The critical analysis allowed us to classify only two
studies (18.2%) as having “good” quality, the rest being scored as “intermediate” (8; 73%) and “poor”
(1; 9%). Evidence exists that salivary miR-940 and miR-3679-5p are reliable markers for pancreatic
cancer and that miR140-5p and miR301a are promising molecules for the salivary diagnosis of gastric
cancer. Conclusions: Further studies, possibly avoiding the risk of bias highlighted here, are necessary
to consolidate these findings and to identify new reliable salivary biomarkers.
Keywords: saliva; biomarkers; miRNA; cancer; diagnosis
1. Introduction
MicroRNAs (miRNAs or miRs) are short non-coding RNA molecules (about 19–23 nucleotides
long) that are involved in the regulation of gene expression at transcriptional and post-translational
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levels. miRNAs constitute one of the most abundant classes of gene-regulatory molecules. They are
consistently part of the transcriptome and their biological influence is widespread; over 30% of the
genome is predicted to be actively regulated by miRNAs, and it has been shown that they are involved
in the regulation of gene expression and in a variety of cell processes such as apoptosis, proliferation,
and differentiation [1].
Different mechanisms have been established as responsible for the miRNAs’ deregulation in
systemic disease and cancer. Genetic alterations such as chromosomal rearrangements, genomic
amplifications, deletions, or point mutations presumptively play an important role in disease initiation and
progression through the aberrant expression of miRNAs located in the affected regions and, subsequently,
by deregulation of their downstream mRNA targets. Gene regulation and gene expression are
obtained through miRNA binding to the 3′-UTR (untranslated region) of mRNAs and the consequent
degradation or translational repression of targeted gene transcripts [2].
The aberrant expression of miRNAs has been associated with a growing number of disease states,
including cancer, inflammatory, and autoimmune diseases [1].
In recent years, interest has raised on miRNAs as potential biomarkers for the diagnosis, prognosis,
and evaluation of treatment efficacy of several diseases. Profiling miRNA expression is likely to not
only allow the identification of a neoplastic tissue and its histological origin, but also to discriminate
between different subtypes of malignant lesions. With regard to inflammation, understanding the role
of miRNAs in its regulation might be important for helping the comprehension of the pathogenesis of
a broad group of diseases [3].
The possibility of evaluating miRNAs in “liquid biopsy” has made rapid progress since 2008,
when circulating miRNAs were detected for the first time in the blood of patients with diffuse large
B-cell lymphoma and prostate cancer [4,5].
Circulating miRNAs have subsequently been found in several other body fluids, including urine,
saliva, and cerebrospinal fluid. The detection of these small molecules in a surprisingly stable form is
due to their association with subcellular vesicle-free particles (usually protein complexes) or to the
packaging into micro-vesicles or exosomes [6].
Saliva has a very complex composition, including enzymes, antibodies, hormones, antimicrobial
elements, and cytokines. For liquid biopsy, saliva presents many advantages over blood, with its
collection being easy, safe, non-invasive, and cost-effective. Salivary diagnostics have disclosed the
existence of several molecular indicators of local and systemic disorders, including cancer [7,8].
Interest in salivary miRNAs as novel non-invasive tools for the diagnosis of cancer and systemic
disease has rapidly increased.
The present systematic review has been designed in order to answer the question “Are salivary
microRNAs reliable biomarkers for diagnosis of cancer and systemic diseases?”, formulated according
to the “Population or problem”, “Intervention or exposure”, “Comparison”, “Outcome” (PICO)
worksheet [9].
2. Results
Search flow is summarized in Figure 1. Multiple databases were searched for titles, abstracts,
and keywords returned 25,868 records; after exclusion of repetitions, 7181 records were screened for
titles and abstracts (see inclusion and exclusion criteria, specified in Table 1).
Thirteen records were eligible for full-text reading. Three records were discarded at this level
(Figure 1).
Cross-reference checks returned one more record which was included in the full-text evaluation phase.
Eleven papers eventually fulfilled the inclusion and exclusion criteria. Table 2 shows the selected
papers and their general characteristics such as title, authors, year of publication, disease investigated,
selected biomarkers, analytical techniques used, and type of saliva collected [10–20].
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Figure 1. Flow-chart diagram for the selection of 11 papers included in the review. 
Figure 1. Flow-chart diagram for the selection of 11 papers included in the review.
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Table 1. Inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
English literature
Studies published between 2000 and 2019
Studies considering human saliva samples for miRNAs identification
Studies using miRNAs as diagnostic biomarkers
Publication type:
case reports, conference proceedings,
personal communications,
letters to editor, reviews
Studies considering salivary miRNAs for diagnostic tools engineering, testing, and validation
Studies on the diagnostic use of salivary miRNAs in patients with:
• Pharyngeal, esophageal, and oral cavity diseases
• oral manifestations of systemic disease
• oral microbial infections
• drug/hormone dosages
• aging
• psychiatric and cognitive diseases
Table 2. General characteristics of the selected papers.
Study Number Title Authors Year ofPublication
Disease
Investigated Number of Involved Patients Biomarkers (miRNAs)
1 [10] MicroRNA signatures differentiateCrohn’s disease from ulcerative colitis Schaefer et al. 2015 CD vs. UC
35 HC, 42 CD,
41 UC,
5 saliva samples/group
miR-101
2 [11] Plasma and saliva miR-21 expression incolorectal cancer patients Sazanov et al. 2016 CRC
31 peripheral blood and 34 saliva
samples
(CRC stages II–IV)
+ 34 HC
miR-21
3 [12]
miR-1246 and miR-4644 in salivary
exosome as potential biomarkers for
pancreatic-biliary tract cancer
Machida et al. 2016 PC 12 PC and 13 HC miR-1246 and miR-4644
4 [13]
miRNA-21 and miRNA-34a Are
Potential Minimally Invasive
Biomarkers for the Diagnosis of
Pancreatic Ductal Adenocarcinoma
Alemar et al. 2016 PC serum and saliva 24 PC + HC saliva,10 PC, and 10 saliva HC
saliva: miR-21, -34a, -155,
-200b, and -376a
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Table 2. Cont.
Study Number Title Authors Year ofPublication
Disease
Investigated Number of Involved Patients Biomarkers (miRNAs)
5 [14] Salivary MicroRNA in PancreaticCancer Patients Humeau et al. 2015 PC
saliva from PC (7), pancreatitis (4),
IPMN (2), and HC (4)
miR-21, miR-23a, miR-23b,
and miR-29c
6 [15]
Salivary microRNAs Show Potential as a
Non-invasive Biomarker for Detecting
Resectable Pancreatic Cancer
Xie et al. 2014 PC 40 PC, 20 BPT, and 40 HC miR-940 and miR-3679-5p
7 [16]
Circulating microRNA Profiles as Liquid
Biopsies for the Characterization and
Diagnosis of Fibromyalgia Syndrome
Masotti et al. 2016 FM Blood and saliva,14 FM, and 14 HC
miR-23a-3p, miR-346, and
miR-320b
8 [17]
Discovery and Validation of Salivary
Extracellular RNA Biomarkers for
Non-invasive Detection of
Gastric Cancer
Li et al. 2018 GC Saliva,63 GC, and 31 HC
miR140-5p, miR374a,
miR454 4.61, miR15b,
miR28–5p, and miR301a
9 [18]
MicroRNA Expression in Salivary
Supernatant of Patients with Pancreatic
Cancer and Its Relationship
with ZHENG
Gao et al. 2014 PC and ZHENG 30 PC and32 HC
5 miRNA candidates
miR-17, miR-21, miR-181a,
miR-181b, and miR-196a
10 [19]
Expression of miR-204 and MMP-9 in
Helicobacter pylori-associated
gastric ulcer
Li et al. 2016
Helicobacter
pylori-associated
GU
Ulcer, blood, and saliva samples of
46 patients with H. pylori-associated
gastritis; normal stomach mucosa,
blood, and saliva in 29 HC
miRNA-204
11 [20]
miRNA Expression Profile of Saliva in
Subjects of Yang Deficiency Constitution
and Yin Deficiency Constitution
Chen et al. 2018
Constitution
deficit and
miRNA
Saliva from 5 balanced individuals,
5 Yin deficiencies, and 5 Yang
deficiencies
81 miRNA Yang deficiency
98 miRNA Yin deficiency
Legend: miRNA: micro RNA; CD: Crohn’s disease; UC: ulcerative colitis; HC: healthy controls; RT qPCR: reverse transcription quantitative polymerase chain reaction; CRC: colon-rectal
cancer; PC: pancreatic cancer (including pancreatic-biliary tract cancer, pancreatic ductal adenocarcinoma); BPT: benign pancreatic tumor; IPMN: intraductal papillary mucinous neoplasm;
FM: fibromyalgia; GU: gastric ulcer.
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2.1. Quality Assessment
A critical appraisal of the selected papers is reported in Figure 2.Int. J. Mol. Sci. 2020, 21, 907 8 of 23 
 
Figure 2. Critical appraisal, including main potential risk of bias and quality score. 
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The case-control study 6 investigated circulating miRNAs for detecting resectable PC, comparing salivary 
specimens of PC patients and HC [15].  
The relationship between PC and ZHENG (a concept of Traditional Chinese Medicine—TCM) was 
studied in paper 9. The expression of salivary miRNAs was investigated in a case-control setting [18]. 
In article 7, salivary and blood miRNA detectability was explored in patients with fibromyalgia (FM) [16]. 
Study 8 was conducted to investigate if salivary miRNAs were reliable biomarkers for the diagnosis of 
gastric cancer (GC) [17]. 
Study 10 investigated the pathogenesis of gastric ulcer in association to Helicobacter pylori by identification 
of selected miRNAs in saliva, serum, and gastric tissues of cases and controls [19]. 
Study 11 explored salivary miRNA expression in subjects of yang or yin deficiency constitution and in 
subjects with balanced constitution, a concept of TCM. Subclassification of patients into these group was performed 
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Salivary analysis from patients with one or the other constitution category and HC allowed the 
identification of specific miRNAs [20]. 
2.4. Type of Saliva and Analytical Techniques 
Figure 2. Critical ap raisal, including main potential risk of bias and quality score.
Disagreement between reviewers occurred in four cases (47%) and all were resolved by discussion
between the two independent assessors as follows:
(a) Paper 1 [10]: divergences involved National Institute of Health (NIH) question number
5, and after discussion, the study was scored as “intermediate”; (b) paper 5 [14] was scored as
“intermediate” by one reviewer and “poor” by the other. Divergences about the use of statistical
analysis were discussed and the paper was scored as “intermediate”; (c) paper 6 [15] was scored as
“good” by one reviewer and “intermediate” by the other. After discussion, the article was scored
as “good”; (d) paper 7 [16] was scored as “poor” and “intermediate” by one and the other assessor,
respectively. After discussion, both reviewers chose to score the study as “poor”.
The most frequently encountered risks of bias (ROBs) were the absence of data regarding the
status of participants (e.g., disease/healthy) to saliva investigators (blind procedure) (10 studies; 91%),
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the lack of sample size justification (nine studies; 82%), the absence of concurrent controls (eight studies;
73%), and the lack of randomization (eight studies; 73%). Less frequent ROBs were the absence of a
comparable population for recruitment and correspondence of timeframe of recruitment (six studies;
54,5%), non-appropriate study question and objectives, in addition to a non-well-defined study
population, and to the choice of non-valid and unreliable inclusion and exclusion criteria (one study).
Two “good” quality researches were identified among the group of the 11 selected studies (18.2%;
studies 6 and 8). Eight records (73%; studies 1, 2, 3, 4, 5, 9, 10, and 11) were classified as “intermediate”,
and one (9%; study 7) was classified as having “poor” quality.
2.2. Level of Evidence
Application of the Oxford Center for Evidence-based Medicine (CEMB) guidelines highlighted
that all of the selected papers have a low level of evidence (4 on 5, the fifth level being the lowest),
because of their case-control or case series design.
2.3. Disease Investigated
Two studies (1 and 2) were focused on colorectal cancer (CRC) and inflammatory bowel diseases
(IBD). Crohn’s disease (CD) was compared with ulcerative colitis (UC) to assess the expression of
salivary miRNA target. Distal adenocarcinoma, an anatomical variant of CRC, was studied in paper 2 to
compare miRNAs in the serum and saliva of cancer patients with those of healthy controls (HC) [10,11].
Four studies investigated pancreatic oncological diseases. Specifically, paper 3 investigated the
presence of two specific miRNAs in salivary exosomes, through a comparison between pancreatic-biliary
tract cancer patients and HC [12].
Serum and saliva from pancreatic ductal adenocarcinoma (PDAC) patients were compared to HC
specimens in study 4: four specific salivary miRNAs targets were investigated [13].
Study 5 was focused on pancreatic cancer (PC); salivary miRNA expression was compared
between patients with PC, pancreatitis, inflammatory conditions, and HC [14].
The case-control study 6 investigated circulating miRNAs for detecting resectable PC, comparing
salivary specimens of PC patients and HC [15].
The relationship between PC and ZHENG (a concept of Traditional Chinese Medicine—TCM) was
studied in paper 9. The expression of salivary miRNAs was investigated in a case-control setting [18].
In article 7, salivary and blood miRNA detectability was explored in patients with fibromyalgia
(FM) [16].
Study 8 was conducted to investigate if salivary miRNAs were reliable biomarkers for the diagnosis
of gastric cancer (GC) [17].
Study 10 investigated the pathogenesis of gastric ulcer in association to Helicobacter pylori by
identification of selected miRNAs in saliva, serum, and gastric tissues of cases and controls [19].
Study 11 explored salivary miRNA expression in subjects of yang or yin deficiency constitution and
in subjects with balanced constitution, a concept of TCM. Subclassification of patients into these group
was performed through the use of Wang Qi’s Body Constitution Classification Questionnaire—Chinese,
version ZYYXH/T 157-2009.
Salivary analysis from patients with one or the other constitution category and HC allowed the
identification of specific miRNAs [20].
2.4. Type of Saliva and Analytical Techniques
Data on type of saliva, methods and procedures of collection, handling, storing, and analytical
techniques are reported in Table 3.
Salivary miRNA identification was conducted onto whole saliva samples in each study.
Particularly, the authors of studies 1, 3, 4, 5, 8, and 11 collected unstimulated saliva, whereas
studies 6 and 10 reported the sampling of saliva through stimulation with citric acid solution. In three
papers (2, 7, and 9), no information on such an aspect was provided.
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Table 3. Collection and analysis of saliva.
Study
Number Authors
Type of Saliva and Methods
of Collection Setting of Collection Handling, Centrifugation, and Storing Method of Analysis
1 [10] Schaefer et al. WholeUnstimulated NR
Preservation: RNAprotect®
saliva reagent (Quiagen)
Centrifugation: NR
Storing: NR
RT-qPCR +
microarray
2 [11] Sazanov et al. WholeNR
In the morning, empty stomach, after
oral rinsing with sterile water
Preservation: NR
Centrifugation:
12,000 rpm, 2 min
Storing: NR
RT-qPCR
3 [12] Machida et al.
Whole
Unstimulated accumulation on
the floor of the mouth
and spit through a funnel
Collection between
7–12 am;
Collection tube kept on ice at 4 ◦C
Preservation: NR
Centrifugation: NR
Storing: at 4 ◦C for 6 h,
then at –80 ◦C
RT-qPCR
4 [13] Alemar et al. WholeUnstimulated
Collection between
9–11 am;
No drinking, eating, smoking, or oral
hygiene for at least 1 h before collection
Preservation:
RNA Oragene® RE-100
Centrifugation:
NR
Storing: NR
RT-qPCR
5 [14] Humeau et al.
Whole
Unstimulated,
collected by micro-pipette
No toothbrushing 45 min before
collection
Preservation:
RNAprotect® saliva reagent (Quiagen)
Centrifugation: NR
Storing: –80 ◦C
RT-qPCR
6 [15] Xie et al.
Whole
Continuous citric acid solution
tongue stimulation for 5 s every
30 s
No eating, drinking, smoking, or oral
hygiene procedures for at least
2 h before collection
Preservation: NR
Centrifugation:
3 mL centrifuged (3000× g, 15 min, 4 ◦C) and
re-centrifugation (12,000× g, 10 min, 4 ◦C)
Storing: –80 ◦C
qPCR
7 [16] Masotti et al. WholeNR NR NR qPCR
8 [17] Li et al. WholeUnstimulated
No eating or drinking except water for
30 min collection
Preservation: SUPERase-In RNase inhibitor®
Centrifugation: 5mL saliva (2600× g for 15 min at 4 ◦C).
Storing: –80 ◦C
RT-qPCR
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Table 3. Cont.
Study
Number Authors
Type of Saliva and Methods
of Collection Setting of Collection Handling, Centrifugation, and Storing Method of Analysis
9 [18] Gao et al. wholeNR NR
Preservation: NR
Centrifugation:
saliva (2500× g for 10 min at 4 ◦C) and
supernatant centrifuged (10,000× g for 1 min)
Storing: −80 ◦C
RT-qPCR
10 [19] Li et al.
whole
Continuous 2% citric acid
tongue stimulation
No eating, drinking, smoking, or oral
hygiene procedures for at least
2 h before collection
NR qPCR + microarray
+ ELISA
11 [20] Chen et al. wholeSwabbing for 15 min
No eating, drinking, smoking, or oral
hygiene procedures for at least
2 h before collection
NR microarray
Legend: miRNA, micro RNA; NR, not reported; RT qPCR, reverse transcription quantitative polymerase chain reaction; CD, Crohn’s disease; UC, ulcerative colitis; CRC, colon-rectal
cancer; PC, pancreatic cancer (including pancreatic-biliary tract cancer, pancreatic ductal adenocarcinoma); FM, fibromyalgia; GU, gastric ulcer.
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Data regarding precise instructions given to patients before saliva collection were available for
eight studies. In six of these (2, 4, 6, 8, 10, and 11), subjects were asked not to eat and drink for a period
of time ranging from 30 min to 2 h before saliva sampling. Patients in study 8 were allowed to drink
water. Additionally, subjects in studies 4, 5, 6, 10, and 11 did not perform oral hygiene procedures
before collection. Patients in studies 4, 6, 10, and 11 were also asked to refrain from smoking. Saliva
was taken in the morning in the three studies (2, 3, and 4) where this information was available.
Most of the studies (8 out of 11; Table 3) reported more or less specific data on handling (including
centrifugation) and storing of saliva. Particularly, centrifugation methods were rather heterogenous, the
most frequently used values ranged between 2500–3000× g for 10 to 15 min at 4 ◦C. It seems worthy to
mention here that supernatants in studies 6 and 9 underwent a second cycle of centrifugation at 12,000× g for
10 min and at 10,000× g for 1 min, respectively. Studies 1, 4, 5, and 8 also reported data on RNA stabilization.
The most frequently reported method of sample storing was freezing at−80 ◦C (studies 3, 5, 6, 8, and 9).
Qualitative and quantitative miRNA expression was investigated by Reverse Transcription
real-time qualitative Polymerase Chain Reaction (RT-qPCR) in 10 studies. One research was performed
through stand-alone miRNA micro-arrays (study 11). Two studies associated micro-arrays to qPCR for
miRNAs detection (studies 1 and 10).
3. Discussion
Salivary analysis is transforming the concept of non-invasive diagnosis, providing novel options
in the panorama of the so-called “liquid biopsy”.
Evidence exists that several salivary biomarkers (including genetics, transcription molecules,
proteins, metabolites, and lipids) can accurately describe peculiar pathological and physiological
states [21]. Examples of diseases that can reliably be diagnosed through salivary analysis are pancreatic
(miR-3679-5p and miR-940) [15], lung (cytokines IL1RN, IL1B, CXCL10) [22], and breast cancers
(phenylalanine, tryptophan) [23], as well as myocardial infarction (C-reactive protein, myoglobin,
and myeloperoxidase) [24].
Among salivary biomarkers, miRNAs seem very promising, both for early diagnosis and for
understanding the pathogenesis of some diseases (e.g., oral cancer, salivary glands cancer, neurological
or psychiatric deficiencies) [25]. Moreover, it has been demonstrated that salivary transcriptome is
very abundant, consisting of thousands of mRNAs and miRNAs [26,27].
Despite the demonstration that the presence of an inflammatory or malignant lesion in a site
distant from the oral cavity is related to peculiar miRNAs in the salivary fluid, such an occurrence
is still poorly understood [28]. It has been speculated that the expression of some miRNAs in saliva
could be very similar to those in serum.
There are several hypotheses trying to explain the detection of cell-free nucleic acids (including
miRNAs) in saliva. It has been reported that blood-derived molecules—entering salivary gland
tissue via various cellular mechanisms, such as transcellular (passive intracellular diffusion and active
transport) or para-cellular routes (extracellular ultrafiltration)—affect the molecular composition of
oral fluids. miRNAs could also be produced locally by apoptosis or cell necrosis, and they could also
be released by normal epithelial or cancerous cells in exosomes or micro vesicles [29,30].
The present systematic review has highlighted a rapidly increasing interest toward the use
of salivary miRNAs for diagnosis of systemic diseases and cancers. Nevertheless, applying strict
inclusion and exclusion criteria for selecting only papers reporting sufficient diagnostic and biochemical
information, the number of studies is limited to 11.
As shown in Table 4, most researches (7 out of 11) showed statistically significant correlations between
one or more miRNAs and the investigated disease. Even though such results would, in general, indicate
that specific salivary miRNAs can contribute to the diagnosis of diseases, our critical appraisal highlighted
that most of the included studies did not satisfy a relevant percentage of items suggested by the NIH
format. Particularly, only two studies received a score indicating “good” quality [18,20]. Furthermore,
the level of evidence of all of the examined studies appears quite low, due to their case-control design.
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Table 4. Statistical significance of salivary miRNAs in association with systemic disease and cancer.
Study Disease Investigatedand Location Salivary miRNAs Subjects Status Sensitivity Specificity
Statistical
Significance
1 [10] Intestinal bowel disease
miR-101 CD vs. HC overexpressed NR NR p < 0.05
miR-21, miR-31,
miR-142-3p UC vs. HC overexpressed NR NR p < 0.05
miR-142-5p UC vs. HC underexpressed NR NR p <0.05
2 [11] Colon-rectal cancer miR-21 CRC stages II/III/IV vs. HC overexpressed 97% 91% p = 5 × 10−12
3 [12] Pancreatic cancer
miR-1246 PC vs. HC overexpressed 66.70% 100% p = 0.008
miR-4644 PC vs. HC overexpressed 75% 76,90% p = 0.026
miR-1246 + miR-4644 PC vs. HC overexpressed NR NR p = 0.005
4 [13] Pancreatic cancer
miR-21 PC vs. HC overexpressed NR NR NR
miR-34a, miR-155,
miR-200b, miR-376a PC vs. HC NR NR NR NR
5 [14] Pancreatic cancer
miR-21 PC vs. HC overexpressed 71% 100% p = 0.012
miR-23a PC vs. HC andpre-cancerous overexpressed 85.70% 100% p = 0.001
miR-23b PC vs. HC andpre-cancerous overexpressed 85.70% 100% p = 0.014
miR-29c PC vs. HC overexpressed 57% 100% p = 0.03
miR-210 Pancreatitis vs. HC overexpressed 100% 100% p = 0.000014
let-7c Pancreatitis vs. HC overexpressed 75% 80% p = 0.033
miR-216 PC vs. Pancreatitis overexpressed 50% 100% p = 0.024
6 [15] Pancreatic cancer
miR-940
PC vs. HC overexpressed 90% 40% p < 0.006
PC vs. BPT overexpressed 62.50% 75% p < 0.004
PC vs. HC + BPT overexpressed 90% 41.70% p < 0.001
miR-3679-5p
PC vs. HC underexpressed 83% 45% p < 0.008
PC vs. BPT underexpressed 90% 45% p < 0.007
PC vs. HC + BPT underexpressed 85% 45% p < 0.002
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Table 4. Cont.
Study Disease Investigatedand Location Salivary miRNAs Subjects Status Sensitivity Specificity
Statistical
Significance
7 [16] Fibromyalgia
miR-23a-3p
FM vs. HC
NR NR NR NR
miR-346 NR NR NR NR
miR-320b NR NR NR NR
8 [17] Gastric Cancer
miR140-5p
GC vs. HC
underexpressed
75% 83%
p < 0.05
miR301a underexpressed
miR374a underexpressed NR NR
miR454 underexpressed NR NR
miR15b underexpressed NR NR
miR28-5p underexpressed NR NR
9 [18] Pancreatic Cancer/ZHENG
miR-17
PC vs. HC
NR NR NR NR
miR-21 NR NR NR NR
miR-181 NR NR NR NR
miR-196a NR NR NR NR
10 [19] Helicobacter pylori-associatedGastric Ulcer miRNR-204 GU vs. HC NR NR NR p < 0.01
11 [20] Constitution deficit/yin yang
miR-4443 Yang deficiency constitution underexpressed NR NR NR
miR-2681-3p overexpressed NR NR NR
miR-4455 Yin deficiency constitution underexpressed NR NR NR
miR-1343-3p overexpressed NR NR NR
Legend: NR, not reported; miRNA, micro RNA; CD, Crohn’s disease; UC, ulcerative colitis; HC, healthy controls; RT qPCR, reverse transcription quantitative polymerase chain reaction;
CRC, colon-rectal cancer; PC, pancreatic cancer (including pancreatic-biliary tract cancer, pancreatic ductal adenocarcinoma); BPT, benign pancreatic tumor; IPMN, intraductal papillary
mucinous neoplasm; FM, fibromyalgia; GU, gastric ulcer.
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ROBs most frequently accounting for decreased quality of the study are the absence of information
on the status of participants (e.g., disease/healthy) to saliva biochemical analysts (blind procedure)
(10 studies; 91%) and the lack of sample size justification (nine studies; 82%).
It is worthy to mention here that one of the studies considered as being of good quality did
not report a sample size justification (study 6). The other (study 8) was conducted following the
principles of the prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) guidelines,
and therefore, even if not clearly reported, it is likely that the authors calculated a sample size [31].
Blinding the status of participants (e.g., the use of anonymous labels) to specimen evaluators
is of paramount importance in researches attempting to identify biomarkers. The absence of a
blinding procedure increases the probability of subjective interpretation of results, thus leading to
misinterpretation of biomarker importance.
The use of untargeted procedures for establishing a relationship between salivary miRNAs and a
specific pathology usually leads to the identification of a large number of molecules. Among these,
only few, if any, will be validated as biomarkers. The process leading to the identification of one reliable
miRNA among the whole group of detected molecules requires a statistically adequate number of
cases. Nevertheless, only a few will be able to reliably represent a pathological state, based on their
statistical significance.
The sample size justification is connected to the sensitivity and specificity of the potential biomarker.
Depending on the number of considered variables, a statistically driven population size selection must
be performed during the design stage; the unbalancing of cases vs. healthy controls could give rise to
confounding results during the selection, verification, and validation stages.
Whole saliva is a mixture of fluids produced by parotid, submandibular, sublingual and minor
salivary glands as well as by the gingival sulcus (crevicular fluid). It is well known that all such
biological liquids vary with regard to their chemico-physiscal properties [32]. Apart from molecules
directly deriving from the body (either from the oral cavity or from distant sites), saliva contains
a myriad of substances produced by microorganisms and of exogenous origin (e.g., food-derived
components). Moreover, saliva quantity and quality from the same subject may be grossly influenced
by factors such as age, gender, circadian rhythm, diet, drugs and environmental exposures [32].
All of the studies included in the present review took into consideration whole saliva specimens.
Apart from the mentioned ROBs, on the basis of the complexity of such fluid, it is crucial to critically
evaluate results, considering variables related to methods and procedures of collection as well as to
handling and storing of samples. Aspects such as oral hygiene sessions and/or food or drink intake in
proximity to the collection of specimens can affect saliva quality and interfere with the identification of
target molecules [33].
Both of the studies considered as being of good quality (6 and 8) reported precise data on
instructions given to patients before saliva collection. However, while study 8 reports a time period
of 2 h, patients of study 6 were asked to refrain from eating and drinking (except for water) for only
30 min before sampling. The variability of procedures adopted demonstrates, to some extent, the lack
of agreement and standardization among groups of researchers and the undoubtful need for further
research in such a specific field.
Centrifugation of specimens is another key factor that may influence transcripts identification,
as contamination may alter microRNA profiles. Both the studies labeled as “good” (6 and 8) report
data on centrifugation, even though they are not comparable. The procedures involving two separate
cycles of centrifugation (studies 6 and 9) seem to be more reliable to obtain acceptable samples for
miRNAs evaluation. Almost half of the studies (5 out of 11) did not report data on centrifugation and
all of these belong to the “intermediate” or “poor” quality categories. As with what was reported for
procedures of collection, also handling of saliva for miRNA analysis requires more research altogether
with the definition of standardized protocols.
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3.1. Pancreatic Cancer
The most investigated disease in the present review was pancreatic cancer (five studies). Such a
tumor is the seventh leading cause of cancer-related deaths worldwide. Because patients rarely exhibit
symptoms until an advanced stage of the disease, pancreatic carcinoma remains one of the most
undiagnosed and lethal malignant neoplasms. Globally, 458,918 new cases were reported in 2018.
Despite advancements in the detection and management of PC, the 5-year survival rate is only 9% [34].
Overall, 18 salivary miRNAs (miR-1246, miR-4644, miR-21, miR-34a, mir-155, miR-200b, miR-376a,
miR-23a, miR-23b, miR-29c, miR-210, miR-216, miR-940, miR-3679-5p, miR-17, miR-18b, miR-18a, and
miR-196a), detected through targeted and untargeted methods, have been studied in relation to the
presence of pancreatic cancer, irrespective of the stage of development of the tumor [12–15,18].
miR-21 is one of the most investigated miRNAs in oncology (e.g., colorectal, thyroid, breast,
ovarian, and cervix cancers) and it is known to inhibit the expression of phosphatases, thus limiting
pathways such as AKT and MAPK [35,36]. This molecule appears to be constantly upregulated in PC
and to be indicative of poor survival, response to treatment, and/or metastatic disease [37].
In the present review, three studies attempted to find a correlation between salivary miR-21 and
PC [13,14,18], with controversial results. Study 4 demonstrated that miR-21 is overexpressed in patients
with PC, even though the results are not statistically significant and therefore the molecule cannot
be used to distinguish patients from healthy controls [13]. On the other hand, studies 5 and 9 report
significant results regarding salivary miR-21 sensitivity and specificity for identifying patients with
PDAC [14,18]. All of these three studies have been classified has having “intermediate” quality.
Apart from patients with PC, miR-21 has been investigated also on patients with CRC and IBD,
within studies considered in the present review (studies 1 and 2). According to our critical appraisal,
the three studies are not labelled as having “good” quality. Nevertheless, it seems worthy to mention
here that the molecule results overexpressed in all the categories of patients. Therefore, such a miRNA
does not seem to be very useful for indicating the presence of a specific disease. The same observation
can be done for miR-23a, which is overexpressed in PC and in fibromyalgia patients.
Study 9 also reported on the association between salivary miRNAs in patients with PC belonging
to three different types of ZHENG. ZHENG is the cornerstone in TCM theories. In cancer occurrence
and its progression, a series of ZHENGs are involved, potentially influencing treatment. According to
the study, miR-17, miR-21, miR-181b, and miR-196 are differently expressed in patients with PC and
with Shi-Re ZHENG, Pi-Xu ZHENG, and Xue-Yu ZHENG [18]. The authors hypothesize that such
differences could give some suggestions about three different pathogeneses of PC. However, it seems
important to highlight here that the paper does report precise hypotheses on pathogenesis, as well as
on criteria for ZHENG differentiation.
miR-1246 and miR-4644 are supposedly involved in tumor initiation, establishment, and metastatic
process [38]. Particularly, salivary expression of miR-1246 is significantly related to serum levels of
the well-known protein CA19-9 [39–41]. It has been speculated that concentration of such miRNA in
saliva is directly associated with concentration of the same molecule in PC tissue [42].
When salivary miR-1246 and miR-4644 are simultaneously taken into consideration, sensitivity
and specificity for PC diagnosis are increased with respect to biomarkers analyzed singularly [13].
miR-940 regulates the 3′-UTR of the GSK3β and sFRP1 genes’ expression, resulting in Wnt/β-catenin
signaling activation. Upregulation of miR-940 suppresses GSK3β and sFRP1 and could promote
pancreatic carcinoma proliferation and invasion [43]. miR-3679-5p seems to activate the cytoskeleton
regulator RNA (CYTOR), which plays a pivotal role in the development and progression of a variety of
cancers [44].
According to the results of study 6, combined analysis of salivary miR-940 and miR-3679-5p has
better discriminatory power than CA19-19 in detecting resectable PC with good sensibility (90% and 83%
for miR-940 and miR-3679-5p, respectively) and acceptable sensitivity (40% and 45%, respectively) [15].
The positive predictive value of the model combining the two miRNAs was 78.9%, and the negative
predictive value was 76.2%. Furthermore, Study 6 was labeled as a “good” quality study after critical
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appraisal. It seems therefore advisable to highlight here the potential important role of salivary miR-940
and miR-3679-5p as reliable markers for PC.
Salivary miR-23a-3p and miR-23b-3p were overexpressed and capable of distinguishing PC patients
from HC and pancreatitis (study 5 [14]) with appreciable sensitivity and specificity; considering the
regulatory role in pancreatic inflammation processes, Grieco et al. [45] described how these miRNAs
were found to regulate the expression of the pro-apoptotic Bcl-2 proteins DP5 and PUMA and
consequent human β-cell apoptosis. These results identify a novel cross-talk between a key family of
miRNAs and pro-apoptotic Bcl-2 proteins in human pancreatic β-cells, broadening our understanding
of cytokine-induced β-cell apoptosis in early type 1 diabetes.
3.2. Gastric Cancer and Gastric Ulcer
According to the GLOBOCAN 2018 data, gastric cancer is the fifth most common neoplasm and
the fifth most deadly cancer, with an estimated 783,000 deaths in 2018 [46].
Among studies of the present review dealing with GC, study 8 was labeled as having “good”
quality [17]. The research reports the analysis of differences in salivary transcriptomics, including
several miRNAs, between a cohort of patients with GC and controls. Particularly, six salivary miRNAs
(miR-140-5p, miR-301a, miR-374a, miR-454, miR-15b, and miR-28-5p) were found to be significantly
downregulated (p < 0.05) in patients without GC, yielding an Area Under Curve values from 0.63 to
0.70, thus being validated as candidate biomarkers. Among these, only two (miR140-5p and miR-301a)
yielded an AUC of 0.81, satisfying a prediction model for diagnosis of GC.
Conversely, it has been demonstrated that miR-140-5p expression is decreased in specimens of
GC, when compared to healthy mucosal tissue [45]. miR-140-5p is able to suppress the proliferation,
migration, and invasion of GC by directly targeting the 3′-UTR of YES1 [47].
The possible discrepancy between extracellular salivary and tissue miR-140-5p seems to deserve
more investigation.
miR-301a is an oncogenic miRNA playing an important role in activating tumor cell invasion/migration,
promoting cell proliferation, inhibiting apoptosis, and enhancing chemosensitivity, both in vivo and
in vitro [48]. With specific regard to GC, it has been shown that the abnormal expression of miR-301a
is associated with cancer progression and poor prognosis [49].
GC incidence and mortality are highly variable by region and highly dependent on diet and
Helicobacter pylori infection [50]. The relationship between infection and expression of salivary miRNA
in relationship to MMP-9 in patient with Helicobacter pylori-associated gastric ulcer was investigated in
study 10 (“intermediate” quality) [19]. Real-time PCR analysis showed that miR-204 was significantly
downregulated in ulcer tissue, blood, and saliva samples from Helicobacter pylori-associated gastritis
patients compared with healthy controls. These results suggest that miR-204 may contribute to the
regulation of Helicobacter pylori-associated gastritis by targeting MMP-9 mRNA.
Many studies have revealed that miR-204 plays a role as a tumor suppressor [51]. Regarding
gastric cancer, validated target genes of miR-204 are BCL-2 [52], EZRIN [53], rabb22a [54], sirt1 [55],
sox4 [56], and usp47 [54].
3.3. Colorectal Diseases
Two studies in the present review were focused on three colorectal diseases (Chron’s disease,
ulcerative colitis, and colorectal cancer) [10,11].
Both studies were judged as having “intermediate” quality.
UC induces diffuse inflammation of the colonic mucosa. CD results in the transmural ulceration
of any portion of the gastrointestinal tract—most often the terminal ileum and colon. Patients affected
by these inflammatory bowel diseases experience symptoms, including diarrhea, abdominal pain,
bloody stools, and vomiting [57,58].
New cases of CD and UC diagnosed each year are approximately 11 and 12 per 100,000 population,
respectively; median age at diagnosis for CD is 34.9 years, while it is 29.5 for UC [59].
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The authors of study 1 [10] identified five salivary miRNAs (miR-21, miR-31, miR142-3p, miR-26a,
and miR-101) in IBD patients. However, all such biomarkers failed to show statistical significance after
applying Bonferroni correction for multiple testing [10].
miR-21 was more present in saliva of patients with UC than in HC. Apart from the well-known role
in tumor promotion and development, miR-21 is also involved in the deregulation of pathways such
as “platelet activation signaling and aggregation”. Platelets emerge as key players in the inflammatory
cascade. The roles of platelets in platelet-mediated inflammation in CD patients and the critical role of
miRNAs in the control of the mechanism of hemostasis may, in part, suggest that both inflammation
and coagulation impairment could contribute to pathogenesis of UC [60].
As for miR-21, salivary levels of miR-31 were found to be overexpressed in UC patients compared
to HC. miR-31 is implicated in several inflammation-associated disorders; its expression signature
could differentiate CD, UC, microscopic colitis, and pediatric IBD. MiR-31 is a major regulator of
Wnt, BMP, and TGF-β signaling, controlling intestinal stem cell proliferation, intestinal homeostasis,
and colorectal cancer progression by binding the 3′-UTR of ERK5, RAS1, TGF-β, β-catenin, and several
other mRNAs to control cell migration, cell proliferation in vitro, and tumorigenesis and metastasis
in vivo [61].
Salivary miR-101 was found to be overexpressed in patients with CD. It has been hypothesized
that miR-101 could restrain the migratory potential of cells by repressing the enhancer of zeste homolog
2 (EZH2) [62]; in fact, in vitro and in vivo studies showed how this peculiar miRNA is decreased in
colon cancer tissues compared with adjacent non-tumor tissues [63]. Moreover, the overexpression of
miR-101 suppresses cell proliferation and inhibits cell migration and invasion in HT-29 and RKO colon
cancer cell lines [64].
Despite the scarce importance in IBD differentiation, the oncogenic role of miR-142-3p is well
known, which promotes cellular invasion in colorectal cancer cells by activating RAC1 and the
onco-suppressive activity of miR-26a, and inhibits cell aggressiveness by regulating FUT4 in CRC [65,66].
Study 2 [11] demonstrated the overexpression of salivary miR-21 among patients with CRC.
The biomarker was tested both for CRC identification and for the discrimination of the stage of disease.
Despite the small sample size, analysis of salivary miR-21 returned a 91% specificity and 97%
sensitivity (p = 5 × 10−12) distinguishing CRC from HC. However, the study was not able to provide a
statistically significant distinction between cancer stages.
3.4. Others (Fibromyalgia, Gastritis, Traditional Chinese Medicine)
Fibromyalgia is a somewhat controversial condition characterized by chronic widespread pain,
unrefreshing sleep, physical exhaustion, and cognitive difficulties. It occurs in all populations
throughout the world, with an overall prevalence between 2% and 4% [67].
In article 7 of the present review [16], salivary and blood miRNA detectability was explored
in order to study FM by the comparison of serum miRNAs in 14 cases and 14 controls (all females,
matched for age). Six serum miRNAs (miR-23a-3p, miR-1, miR-133a, miR-346, miR-139-5p, and
miR-320b) resulted significantly deregulated. Particularly, among patients with FM, miR-1 showed the
greatest downregulation, followed by miR-23a-3p. Six statistically dysregulated target biomarkers
were selected for the salivary investigation. Interestingly, only three miRNAs were detectable both in
serum and saliva (miR-23a-3p, miR-346, and miR-320b). However, though being detectable, salivary
miRNA expression values were not statistically different if compared to controls [19].
The biological effects dependent on genes targeted by dysregulated miRNAs in FM patients
are, to different levels, involved in muscular atrophy, epilepsy and autism (miR23a-3p), myoblast
differentiation and modulation of brain-derived neurotrophic factor (BDNF) expression (miR-1);
myoblast differentiation (miR-133a), immune response (miR-346), brain development (miR-139-5p),
neuron development, autism, and complex regional pain syndrome (miR-320p) [16].
In the context of TCM, study 11 explored salivary miRNAs expression in subjects of Yang or Yin
deficiency constitution, as well as in subjects with a balanced constitution [20].
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Yang deficiency and Yin deficiency constitution accounts for 9.0% and 8.3% of the distribution of
nine constitutions of the TCM, respectively [68]. These unbalanced constitutions are considered to be
related to diseases or are the risk factors of diseases. According to the authors, the research on TCM
constitution has important clinical significance in the prediction and prevention of diseases [20].
Therefore, trying to find a relationship between the expression of salivary miRNAs and TCM
constitutions, they attempted to establish a direct correlation between specific salivary molecules and
the prediction of development of certain diseases. Such an association, however, seems, to some
extent, somewhat artificial and not evidence-based, as none of the subjects included in Study 11 had
specific diseases. Moreover, the criteria for identification of TCM constitutions are entirely based on
self-reporting (questionnaire) and not on objective findings.
Differences in expression were highlighted for miR-4443 and miR-2681-3p in Yang deficiency
constitution (main characteristic: cold intolerance) and for miR-4455 and miR-1343-3p in Yin deficiency
constitution (main characteristic: heat intolerance). A role in thermoregulation is played by thyroid
hormones T3 and T4 (triiodothyronine and thyroxine). In 2017, Yicheng et al. described how T
CD4+ cells play a significant role in the pathogenesis of Graves’ disease, a common immuno-mediate
condition; lymphocytic infiltration in thyroid gland leads to the production of autoantibody against
thyroid-stimulating hormone receptor (TSH-r), which mimics the action of TSH, causing excessive
thyroid hormone production and hyperthyroidism. miR-4443 can induce overexpression of cytokines,
chemokines, and the proliferation of CD4+ T cells in vitro. The authors indicated that miR-4443 was
elevated in GD patients and was significantly correlated with GD immune-pathogenesis [69].
Moreover, Shefler et al. recently reported that miR-4443 was present in micro-vesicles derived
from activated T cells, which regulate mast cell activation by targeting PTPRJ gene, suggesting a role of
miR-4443 as a regulator of inflammation [70].
The heterogeneity of the diseases investigated, as well as of salivary miRNAs, did not allow us to
perform a meta-analysis of the studies included in the present review. Even when limiting the analysis
to single groups of diseases (e.g., pancreatic cancer), researches report the experience of patients at
different stages, therefore limiting the possibility of pooling data.
In conclusion, according to our critical appraisal, only two studies on salivary miRNAs have been
performed following appropriate methodologies [15,17]. According to such studies, salivary miR-940
and miR-3679-5p seem to be reliable markers for pancreatic cancer, and miR140-5p and miR301a are
promising molecules for the salivary diagnosis of gastric cancer.
Further studies, possibly avoiding the ROBs highlighted here, are necessary to consolidate these
findings and to identify new reliable salivary biomarkers.
4. Materials and Methods
The Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) statement was
used to guide the present work [71].
4.1. Search Strategy
A multiple database research (Medline, Web of Science, Scopus) was set, using as entry terms:
saliva and miRNA; saliva and microRNA; salivary miRNA; salivary miR; saliva and cancer; saliva
and carcinoma; and saliva and malignancies. A periodic screening of the databases was performed
between June 2018 and May 2019.
Only literature in English, published after 2000, was taken into consideration. Duplicates resulting
from the initial database querying were discarded through End Note X9©, Clarivate Analytics,
software aid.
First level screening was performed on titles, abstracts, and keywords by two independent
investigators. In the case of controversial titles/abstract, full-texts were evaluated.
At the title/abstract screening level, case reports, conference proceedings, personal communications,
letters to editor, and reviews were excluded.
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Studies specifically reporting on biochemical methods, technological aspects, devices used,
or proposed for saliva evaluation or detection of specific molecules were excluded.
The present systematic review takes into consideration only salivary miRNAs presumptively
originating from tissues different from those in direct conjunction with the oral cavity. Therefore,
we excluded studies evaluating miRNAs in the saliva of patients with pharyngeal, esophageal,
salivary glands or oral cavity diseases, oral manifestations of systemic diseases, microbial infections,
and drug/hormone dosages were excluded.
Studies considering miRNA expression in relationship to injuries/trauma and physical activity
were not included. Furthermore, papers dealing with drug/hormone dosages were not considered.
Moreover, papers investigating the association between salivary miRNAs and aging, psychiatric
diseases, dementia, and cognitive evaluation were excluded. Studies on in vitro or animal models
were also excluded. The use of salivary miRNAs for forensic purposes was not considered.
Inclusion and exclusion criteria are summarized in Table 1.
Literature eligible on the selected inclusion/exclusion criteria and reviews were double-checked,
including reference lists, in order to identify papers possibly not considered in the previous selection.
Considering the study period and recruitment centers, a further assessment was performed to
identify possible overlapping series of patients. Wherever multiple studies reported the same set
of data in fully detectable series, only the most recent or the most complete series were included in
the review.
4.2. Data Extraction, Quality Assessment, and Critical Appraisal
Information extracted from each study was summarized into an Excel table (Office Suite, Microsoft
Corp.) which considered: title, authors, year of publication, disease investigated, number of involved
patients, biomarkers (miRNAs), type of analytic device, type of saliva, and statistical significance.
Questionnaires issued by the National Heart, Lung, and Blood Institute within the National
Institute of Health and called “Study Quality Assessment Tool” were used [72]. Such tools were
specifically developed for each type of study (controlled intervention studies, systematic reviews
with meta-analysis, observational cohort and cross-sectional studies, case-control studies, before–after
studies without control group, case series studies) and they were answered by two independent
investigators. Additionally, the number of patients enrolled in each study was taken into consideration.
Critical appraisal of studies has been summarized through assignation of a score ranging from 0%
to 100%, based on the percentage of “yes” choices on the overall number of answers given. Studies
having 80–100% score were labeled as “good”; those ranging from 50% to 70% were “intermediate”;
and studies scoring less than 50% were defined as “poor”.
The level of evidence was assessed using the classification of the Oxford Center for Evidence-Based
Medicine levels for diagnosis (2011) [73].
Disagreements were resolved by discussion between the reviewers.
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